BeiGene, Ltd/$ONC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeiGene, Ltd
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Ticker
$ONC
Sector
Primary listing
Employees
11,000
Headquarters
Basel, Switzerland
Website
BeiGene, Ltd Metrics
BasicAdvanced
$34B
-
-$1.66
0.21
-
Price and volume
Market cap
$34B
Beta
0.21
52-week high
$355.30
52-week low
$174.74
Average daily volume
229K
Financial strength
Current ratio
2.922
Quick ratio
1.645
Long term debt to equity
25.315
Total debt to equity
25.315
Interest coverage (TTM)
-3.41%
Profitability
EBITDA (TTM)
79.151
Gross margin (TTM)
63.45%
Net profit margin (TTM)
-3.89%
Operating margin (TTM)
-2.23%
Effective tax rate (TTM)
-181.05%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-1.06%
Return on equity (TTM)
-4.98%
Valuation
Price to revenue (TTM)
7.262
Price to book
9.03
Price to tangible book (TTM)
9.03
Price to free cash flow (TTM)
200.979
Free cash flow yield (TTM)
0.50%
Free cash flow per share (TTM)
1.543
Growth
Revenue change (TTM)
47.33%
Earnings per share change (TTM)
-66.85%
3-year revenue growth (CAGR)
62.22%
10-year revenue growth (CAGR)
83.33%
3-year earnings per share growth (CAGR)
-56.84%
10-year earnings per share growth (CAGR)
-7.36%
Bulls say / Bears say
BeiGene turned GAAP profitable for the first time in Q1 2025, posting net income of $1.27 million versus a $251.15 million loss in Q1 2024, thanks to a 49% year-over-year revenue growth to $1.12 billion.
Global sales of Brukinsa jumped 62% year-over-year to $792 million in Q1 2025, with U.S. sales rising 60% to $563 million and the drug becoming the market leader for new CLL patient starts across all lines of therapy.
The EMA’s CHMP issued a positive opinion on March 31, 2025, recommending Tevimbra for first-line treatment of extensive-stage small cell lung cancer, expanding BeiGene’s solid tumor immunotherapy opportunities in Europe.
BeiGene’s Q1 2025 revenue of $1.12 billion missed consensus forecasts of $1.13 billion, causing shares to fall more than 5% in pre-market trading and underscoring how sensitive investors are to growth expectations.
Brukinsa made up about 73% of Q4 2024 revenue ($828 million out of $1.13 billion), concentrating BeiGene’s top-line performance around a single product that faces competitive threats and patent expiration risk.
BeiGene monetized as much as $950 million in future royalties from its small cell lung cancer drug Imdelltra in a deal with Royalty Pharma, signaling a reliance on non-dilutive financing that may come at the expense of future cash flows.
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
BeiGene, Ltd News
AllArticlesVideos
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
Business Wire2 days ago
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
Business Wire4 days ago
BeOne Medicines' Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeiGene, Ltd stock?
BeiGene, Ltd (ONC) has a market cap of $34B as of October 24, 2025.
What is the P/E ratio for BeiGene, Ltd stock?
The price to earnings (P/E) ratio for BeiGene, Ltd (ONC) stock is 0 as of October 24, 2025.
Does BeiGene, Ltd stock pay dividends?
No, BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next BeiGene, Ltd dividend payment date?
BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene, Ltd?
BeiGene, Ltd (ONC) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.